The FTC has approved an amended final order settling charges that Teva's (TEVA +1.3%) proposed...

|About: Teva Pharmaceutical Industr... (TEVA)|By:, SA News Editor

The FTC has approved an amended final order settling charges that Teva's (TEVA +1.3%) proposed acquisition of Cephalon would have been anti-competitive for several generic drugs. The order requires Teva to sell the rights and assets related to a generic cancer pain drug and a generic muscle relaxant to Par Pharmaceuticals (PRX -0.6%), and  allow PRX to sell a generic version of Cephalon's narcolepsy drug Provigil in 2012.